Study to Compare Sevelamer Carbonate Powder to Sevelamer Hydrochloride Tablets in Patients With CKD on Hemodialysis

Inclusion Criteria:

• On three times per week hemodialysis for three months or longer

• Currently on a phosphate binder(s)

• Considered compliant with phosphate binders and hemodialysis therapy

• Willing to avoid any intentional changes in diet such as fasting or dieting

• Have the following documented local laboratory measurements:a.Two most recentconsecutive serum phosphorus measurements that are ≥ 3.0 and ≤ 6.5 (6.5) mg/dL within 60 days of screening; b.A most recent intact parathyroid hormone (iPTH) measurement ≤ 800 pg/mL within 90 days of screening

• Have the following central laboratory measurements: a.A serum phosphorus measurement > 5.5 mg/dL at randomization (Week 0);b.A serum iPTH measurement ≤ 800 pg/mL atscreening

• Have not participated in any other investigational drug studies within 30 days priorto enrollment

• Level of understanding and willingness to cooperate with all visits and procedures asdescribed by the study personnel

• Willing and able to take sevelamer alone as a phosphate binder for the duration of thestudy

• Willing and able to maintain screening doses of lipid medication for the duration ofthe study, except for safety reasons

• Willing and able to avoid antacids and phosphate binders containing aluminum,magnesium, calcium or lanthanum for the duration of the study unless prescribed as anevening calcium supplement

• If female and of childbearing potential (pre-menopausal and not surgically sterile),willing to use an effective contraceptive method throughout the study, which includesbarrier methods, hormones, or intrauterine devices (IUDs)

• Life expectancy of 12 months or greater

• Willing and able to provide informed consent

Exclusion Criteria:

• Active bowel obstruction, dysphagia, swallowing disorder, or severe gastrointestinal (GI) motility disorders

• Active ethanol or drug abuse, excluding tobacco use

• In the opinion of the Investigator, subject has poorly controlled diabetes mellitus,poorly controlled hypertension, active vasculitis, HIV infection, or any clinicallysignificant unstable medical condition

• Use of anti-arrhythmic or anti-seizure medications for the use of arrhythmia orseizure disorders

• Known hypersensitivity to sevelamer or any constituents of the study drug

• Pregnant or breast-feeding

• Evidence of active malignancy except for basal cell carcinoma of the skin

• Unable to comply with the requirements of the study

• Any other condition which, in the opinion of the Investigator, will prohibit thesubject's inclusion in the study